SAN DIEGO, Aug. 31, 2016 /PRNewswire/ -- Halozyme
Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company
developing novel oncology and drug-delivery therapies, will be
presenting at the Wells Fargo Healthcare Conference in Boston on Weds., Sept.
7 at 4:05 p.m. ET/1:05 p.m. PT. and at the Baird Global
Healthcare Conference in New York
on Thurs., Sept. 8 at 1:25 p.m. ET/10:25 a.m.
PT. Dr. Helen Torley,
president and CEO, will represent the company at both
conferences.
The sessions will be webcast through the "Investors" section of
Halozyme's corporate website at www.halozyme.com, and a recording
will be made available for 90 days following each event. To access
the live webcast, please log on to Halozyme's website approximately
15 minutes early to register and download any necessary audio
software.
About Halozyme
Halozyme Therapeutics is a
biotechnology company focused on developing and commercializing
novel oncology therapies that target the tumor microenvironment.
Halozyme's lead proprietary program, investigational drug PEGPH20,
applies a unique approach to targeting solid tumors, allowing
increased access of co-administered cancer drug therapies to the
tumor in animal models. PEGPH20 is currently in development for
metastatic pancreatic cancer, non-small cell lung cancer, gastric
cancer, metastatic breast cancer and has potential across
additional cancers in combination with different types of cancer
therapies. In addition to its proprietary product portfolio,
Halozyme has established value-driving partnerships with leading
pharmaceutical companies including Roche, Baxalta, Pfizer, Janssen,
AbbVie and Lilly for its ENHANZE™ drug delivery platform. Halozyme
is headquartered in San Diego. For
more information visit www.halozyme.com.
Contacts:
Jim
Mazzola
858-704-8122
ir@halozyme.com
Chris Burton
858-704-8352
ir@halozyme.com
Logo -
http://photos.prnewswire.com/prnh/20100302/LA63139LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/halozyme-therapeutics-to-present-at-upcoming-healthcare-conferences-300320905.html
SOURCE Halozyme Therapeutics, Inc.